Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Thorax 2005;60:617a
Copyright © 2005 BMJ Publishing Group Ltd & British Thoracic Society
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wedzicha, W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wedzicha, W.
Topic Collections
Right arrowRelevant Articles

Airwaves

Wisia Wedzicha, Editor in Chief

The first 150 words of the full text of this article appear below.


SILDENAFIL AT HIGH ALTITUDE
In this issue of Thorax Aldashev et al remind us that high altitude pulmonary hypertension (HAPH) is an important public health problem, and that 140 million people live at an altitude above 2500 metres. The pathophysiology underlying HAPH is still poorly understood, but involves vascular remodelling. Phosphodiesterase (PDE) 5 is the major PDE found in pulmonary vasculature, and some earlier studies have suggested that it may have a role in pulmonary hypertension. The authors screened subjects in the mountainous Naryn region of Kyrgyzstan (altitude 2500–4000 m above sea level), and those with a raised pulmonary artery pressure were randomised to receive either the PDE5 inhibitor sildenafil at two dosages or placebo for 12 weeks. Patients receiving sildenafil at the lower dose showed a fall in pulmonary artery pressure and improvement in walking distance. The authors conclude that sildenafil, although expensive for a country with poor health resources, is a potentially . . . [Full text of this article]


Relevant Articles

Impact of changes in the International Olympic Committee Medical Commission criteria for asthma
L-P Boulet
Thorax 2005 60: 618-620. [Extract] [Full Text] [PDF]

Impact of changes in the IOC-MC asthma criteria: a British perspective
J W Dickinson, G P Whyte, A K McConnell, and M G Harries
Thorax 2005 60: 629-632. [Abstract] [Full Text] [PDF]

Neutrophil cell death, activation and bacterial infection in cystic fibrosis
A P Watt, J Courtney, J Moore, M Ennis, and J S Elborn
Thorax 2005 60: 659-664. [Abstract] [Full Text] [PDF]

Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study
M M van der Eerden, F Vlaspolder, C S de Graaff, T Groot, W Bronsveld, H M Jansen, and W G Boersma
Thorax 2005 60: 672-678. [Abstract] [Full Text] [PDF]

Phosphodiesterase type 5 and high altitude pulmonary hypertension
A A Aldashev, B K Kojonazarov, T A Amatov, T M Sooronbaev, M M Mirrakhimov, N W Morrell, J Wharton, and M R Wilkins
Thorax 2005 60: 683-687. [Abstract] [Full Text] [PDF]

Regulation of brain-derived neurotrophic factor (BDNF) during sleep apnoea treatment
R Staats, P Stoll, D Zingler, J C Virchow, and M Lommatzsch
Thorax 2005 60: 688-692. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 BMJ Publishing Group Ltd & British Thoracic Society